Search
Influenza B virus B/Massachusetts/2/2012 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB11000ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 KitTechnetium Tc-99m pyrophosphate
go.drugbank.com/drugs/DB09165ApprovedIt has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. … A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process.
Categories: Compounds used in a research, industrial, or household settingInfluenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15788ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeUdenafil
go.drugbank.com/drugs/DB06267ApprovedUdenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. … It is not yet approved for use in the U.S., E.U., or Canada.
Categories: Drugs Used in Erectile DysfunctionAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing
Methylchloroisothiazolinone
go.drugbank.com/drugs/DB14197ApprovedMethylchloroisothiazolinone (MCI) is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.
Categories: Compounds used in a research, industrial, or household settingSynonyms: 5-Chloro-N-methylisothiazolin-3-oneReslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalCinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype. … In addition, a significant improvement in lung function was seen, as measured by the volume of air exhaled by patients in one second [L1133].
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14385ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeFelbamate
go.drugbank.com/drugs/DB00949ApprovedFelbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). … Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Mirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigational[L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.